Amgen AMGN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| Aranesp | $1.39B+3.5% | $1.34B-1.5% | $1.36B-4.2% | $1.42B-4.0% | |
| BLINCYTO | $1.56B+28.2% | $1.22B+41.2% | $861M+47.7% | $583M+23.5% | |
| ENBREL | $2.23B-32.9% | $3.32B-10.3% | $3.7B-10.2% | $4.12B-7.8% | |
| EVENITY | $2.1B+34.4% | $1.56B+34.7% | $1.16B+47.4% | $787M+48.5% | |
| KRYSTEXXA | $1.34B+13.1% | $1.19B+336% | $272M— | $0— | |
| KYPROLIS | $1.41B-6.1% | $1.5B+7.1% | $1.4B+12.5% | $1.25B+12.5% | |
| Nplate | $1.52B+4.7% | $1.46B-1.4% | $1.48B+13.9% | $1.3B+26.3% | |
| Otezla | $2.27B+6.5% | $2.13B-2.8% | $2.19B-4.4% | $2.29B+1.7% | |
| Other products | $7.09B+26.0% | $5.63B+19.9% | $4.7B-7.0% | $5.05B-11.6% | |
| Prolia | $4.41B+0.9% | $4.37B+8.1% | $4.05B+11.6% | $3.63B+11.7% | |
| Repatha | $3.02B+35.7% | $2.22B+35.9% | $1.64B— | —— | |
| TEPEZZA | $1.9B+2.8% | $1.85B+313% | $448M— | $0— | |
| TEZSPIRE | $1.48B+52.1% | $972M+71.4% | $567M+234% | $170M— | |
| Vectibix | $1.18B+12.4% | $1.05B+6.2% | $984M+10.2% | $893M+2.3% | |
| XGEVA | $2.08B-6.3% | $2.23B+5.4% | $2.11B+4.9% | $2.01B-0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amgen break its business down?
- Amgen (AMGN) reports total revenues by product across 18 parts — Aranesp, BLINCYTO, ENBREL, EVENITY and IMDELLTRA/IMDYLLTRA. Each is extracted from the segment footnotes and tracked over time.
- Where does Amgen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amgen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
